Evorel 1,6 mg/ 3,2 mg/ 4,8 mg/ 6,4 mg Transdermal patch.
PDF Leaflet Revision Date: 17 December 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of menopausal symptoms and prevention of post-menopausal osteoporosis.
Dosage (summary)
Apply twice weekly; initiate with EVOREL 50, adjust as needed.
Special Populations
- Elderly
- Liver impairment
- Kidney impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Barbiturates
- Carbamazepine
- Rifampicin
- St. John's wort
- Lamotrigine
Contraindications
- Hypersensitivity to estrogen
- Breast cancer
- Endometrial cancer
- Undiagnosed genital bleeding
- Active liver disease
- Thromboembolic disorders
Common side effects
- Headache
- Breast pain
- Nausea
- Dizziness
- Application site reactions
Counselling Points
- Apply to clean, dry skin
- Change patch every 3-4 days
- Report any unusual bleeding
- Avoid use during pregnancy
Serious warnings
- Increased risk of breast cancer
- Risk of thromboembolism
- Monitor for endometrial hyperplasia
Important Disclaimer
The Evorel 1,6 mg/ 3,2 mg/ 4,8 mg/ 6,4 mg Transdermal patch. professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
